Bcl11b Sustains Multipotency and Restricts Effector Programs of Intestinal-Resident Memory CD8+ T cells - The networks of transcription factors (TFs) that control intestinal-resident memory CD8+ T (TRM) cells, including multipotency and effector programs, are poorly understood. In this study published in Science Immunology, a team of researchers including Vice Chair Dorina Avram, PhD, investigated the role of the TF Bcl11b in TRM cells during infection with Listeria monocytogenes using mice with post-activation, conditional deletion of Bcl11b in CD8+ T cells.
Moffitt Researchers Identify Molecular Pathway That Controls Immunosuppression in Tumors - The Moffit team reveals how protein-signaling pathways associated with cellular stress processes turn myeloid cells into tumor-promoting players and suggests that targeting the PERK protein may be an effective therapeutic approach to reactivate the immune system and boost the effectiveness of immunotherapy.
Moffitt Researchers Characterize Mechanism of Action of CAR T Cells - In order to better understand how CAR T cells function, a multidisciplinary team of Moffitt researchers used a variety of approaches based on proteomics to compare CAR T cells that targeted the same molecule on cancer cells, but differed in their intracellular design and antitumor activity.
S100A9-Induced Overexpression of Pd-1/Pd-L1 Contributes to Ineffective Hematopoiesis In Myelodysplastic Syndromes - D-1/PD-L1 blockade therapy, alone or in combination with other strategies, may have therapeutic potential to restore and promote effective hematopoiesis in MDS, according to new research from Moffitt Cancer Center that was published in Nature.com.
Moffitt Researchers Discover New Approach to Stimulate an Immune Response Against Tumor Cells - In an article published in the January issue of Cancer Cell, the researchers describe how a new type of immunotherapy drug targeting the protein TIM-3 works to stimulate the immune system.
Bacteriotherapy Heals Cisplatin Damage - Bacteriotherapy with fecal pellets before chemotherapy reduces intestinal damage and systemic inflammation in response to cisplatin, according to new research from Moffitt Cancer Center that was published online by The Journal of Leukocyte Biology.
Moffitt Researchers Identify Novel Target to Improve Chemotherapeutic Response in Breast Cancer - In an article published in the January issue of Cancer Cell, members of the Department of Immunology at Moffitt report that TIM-3 is expressed by intratumoral CD103+ dendritic cells – the cells responsible for the initial activation of anti-tumor T cells – and alters their immunostimulatory function.
ITUS Enters CAR-T Research Alliance with Moffitt Cancer Center - ITUS Corporation, a cancer-focused biotechnology company, has entered into a Cooperative Research and Development Agreement with Moffitt Cancer Center, to advance toward human clinical testing a Chimeric Receptor T-Cell technology aimed initially at ovarian cancer, and eventually additional solid tumors.
Fighting Cancer with Mathematics and Viruses - The laboratory of Daniel Abate-Daga, in collaboration with members of the Integrated Mathematical Oncology group, has published a review that made the cover of the journal "Viruses."
National Heart, Lung, and Blood Institute selects Moffitt Cancer Center as one of the Cell Therapies Processing Facilities - Moffitt Cancer Center is one of the five institutions selected as a Cell Therapies Processing Facility by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).